NAD Market Competition And Regulatory Risks Will Challenge Margins Yet Support Long-Term Healthy Aging Demand

AnalystLowTarget

Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

14 Dec 25

Updated

14 Jul 26

Views

Not Invested

Shared on 14 Jul 26

Fair value Decreased 25%

NAGE: Rare Disease Drug Designations Will Drive Future Longevity Upside

Niagen Bioscience wins new FDA and European “rare disease” designations for its lead drug candidate, marking a push into regulated drug development beyond supplements. But analysts are also cooling on the near-term story as the company raises the option to issue more shares and faces tougher questions about how quickly it can turn longevity buzz into steady growth.

5 views

Fair Value vs Share Price

US$9

vs US$3.2863.6% undervalued

15.2%

Revenue growth

12.9%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Niagen Bioscience

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Flawless balance sheet and good value.

Market capUS$271.4m

PB3.2x

Estimated Growth12.6%

Dividend YieldN/A

Full analysis

CEO & management

Robert Fried

CEO

6.4yrs

CEO Tenure

Operates as a bioscience company engages in developing healthy aging products.